These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 17029129)

  • 1. Progression of Pneumocystis jiroveci pneumonia in patients receiving echinocandin therapy.
    Kamboj M; Weinstock D; Sepkowitz KA
    Clin Infect Dis; 2006 Nov; 43(9):e92-4. PubMed ID: 17029129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment with echinocandin in an HIV-infected individual failing first-line therapy for Pneumocystis jirovecii pneumonia.
    Ceballos ME; Ortega M; Andresen M; Wozniak A; García P; Balcells ME
    AIDS; 2011 Nov; 25(17):2192-3. PubMed ID: 22019819
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment and prevention of Pneumocystis carinii pneumonia and further elucidation of the P. carinii life cycle with 1,3-beta-glucan synthesis inhibitor L-671,329.
    Schmatz DM; Powles M; McFadden DC; Pittarelli LA; Liberator PA; Anderson JW
    J Protozool; 1991; 38(6):151S-153S. PubMed ID: 1818147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined trimethoprim and caspofungin treatment for severe Pneumocystis jiroveci pneumonia in a five year old boy with acute lymphoblastic leukemia.
    Beltz K; Kramm CM; Laws HJ; Schroten H; Wessalowski R; Göbel U
    Klin Padiatr; 2006; 218(3):177-9. PubMed ID: 16688676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pneumocystis jiroveci pneumonia in a patient with Wegener's granulomatosis treated efficiently with caspofungin.
    Hof H; Schnülle P
    Mycoses; 2008; 51 Suppl 1():65-7. PubMed ID: 18471163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Echinocandin antifungals: review and update.
    Morrison VA
    Expert Rev Anti Infect Ther; 2006 Apr; 4(2):325-42. PubMed ID: 16597212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of caspofungin and the echinocandins in the antifungal armamentarium.
    Morrison VA
    Curr Opin Investig Drugs; 2002 Oct; 3(10):1432-6. PubMed ID: 12431014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The echinocandins.
    Cappelletty D; Eiselstein-McKitrick K
    Pharmacotherapy; 2007 Mar; 27(3):369-88. PubMed ID: 17316149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Echinocandins as alternative treatment for HIV-infected patients with Pneumocystis pneumonia.
    Huang YS; Liu CE; Lin SP; Lee CH; Yang CJ; Lin CY; Tang HJ; Lee YC; Lin YC; Lee YT; Sun HY; Hung CC;
    AIDS; 2019 Jul; 33(8):1345-1351. PubMed ID: 30932964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paradoxical increase in circulating Aspergillus antigen during treatment with caspofungin in a patient with pulmonary aspergillosis.
    Klont RR; Mennink-Kersten MA; Ruegebrink D; Rijs AJ; Blijlevens NM; Donnelly JP; Verweij PE
    Clin Infect Dis; 2006 Aug; 43(3):e23-5. PubMed ID: 16804836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Caspofungin: a major breakthrough in treatment of systemic fungal infections.
    Agarwal MB; Rathi SA; Ratho N; Subramanian R
    J Assoc Physicians India; 2006 Dec; 54():943-8. PubMed ID: 17334012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of current antifungal agents and their targets within the Pneumocystis carinii genome.
    Porollo A; Meller J; Joshi Y; Jaiswal V; Smulian AG; Cushion MT
    Curr Drug Targets; 2012 Nov; 13(12):1575-85. PubMed ID: 22934582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Echinocandins--new antifungal agents.
    Stan CD; Tuchiluş C; Stan CI
    Rev Med Chir Soc Med Nat Iasi; 2014; 118(2):528-36. PubMed ID: 25076727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Echinocandin antifungal drugs.
    Denning DW
    Lancet; 2003 Oct; 362(9390):1142-51. PubMed ID: 14550704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Pneumocystis carinii pneumonia with 1,3-beta-glucan synthesis inhibitors.
    Schmatz DM; Romancheck MA; Pittarelli LA; Schwartz RE; Fromtling RA; Nollstadt KH; Vanmiddlesworth FL; Wilson KE; Turner MJ
    Proc Natl Acad Sci U S A; 1990 Aug; 87(15):5950-4. PubMed ID: 2198575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased dose of echinocandins for invasive fungal infections: bonanza for the patient or the pharmaceutical industry?
    Chandrasekar PH
    Bone Marrow Transplant; 2007 Feb; 39(3):129-31. PubMed ID: 17245422
    [No Abstract]   [Full Text] [Related]  

  • 17. LY 303366. ECB.
    Drugs R D; 1999 Feb; 1(2):176-8. PubMed ID: 10566019
    [No Abstract]   [Full Text] [Related]  

  • 18. Prophylactic effect of FK463, a novel antifungal lipopeptide, against Pneumocystis carinii infection in mice.
    Ito M; Nozu R; Kuramochi T; Eguchi N; Suzuki S; Hioki K; Itoh T; Ikeda F
    Antimicrob Agents Chemother; 2000 Sep; 44(9):2259-62. PubMed ID: 10952565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Semisynthetic echinocandins affect cell wall deposition of Pneumocystis carinii in vitro and in vivo.
    Bartlett MS; Current WL; Goheen MP; Boylan CJ; Lee CH; Shaw MM; Queener SF; Smith JW
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1811-6. PubMed ID: 8843286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pneumocystis pneumonia--a retrospective study 1991-2001 in Gothenburg, Sweden.
    Mikaelsson L; Jacobsson G; Andersson R
    J Infect; 2006 Oct; 53(4):260-5. PubMed ID: 16403575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.